Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to $38.0 million.

  • Northwest Biotherapeutics' Total Non-Current Liabilities rose 11.63% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 11.63%. This contributed to the annual value of $37.4 million for FY2024, which is 25.97% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Total Non-Current Liabilities of $38.0 million as of Q3 2025, which was up 17.64% from $32.3 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Total Non-Current Liabilities ranged from a high of $38.0 million in Q3 2025 and a low of $10.1 million during Q3 2022.
  • Over the past 3 years, Northwest Biotherapeutics' median Total Non-Current Liabilities value was $29.7 million (recorded in 2023), while the average stood at $28.6 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Total Non-Current Liabilities soared by 392.71% in 2021, and later crashed by 65.90% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Total Non-Current Liabilities (Quarterly) stood at $30.4 million in 2021, then tumbled by 65.90% to $10.4 million in 2022, then soared by 186.81% to $29.7 million in 2023, then increased by 25.97% to $37.4 million in 2024, then increased by 11.63% to $38.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $38.0 million for Q3 2025, versus $32.3 million for Q2 2025 and $29.3 million for Q1 2025.